The company's financial position is precarious, evidenced by a massive accumulated deficit of -$113.9M and a reliance on equity-based funding to support its $19.8M asset base.
| Total Current Assets | 5.91M | 7.35M | 1.05M | 1.75M | 3.94M | 2.18M | 224.75K | 505 | 153.56K | 383 |
| Cash & Short-Term Investments | 5.26M | 6.35M | 532.88K | 1.47M | 3.79M | 2.18M | 202.97K | 505 | 153.56K | 383 |
| Cash Only | 5.21M | 5.67M | 532.88K | 1.47M | 3.79M | 2.18M | 202.97K | 505 | 153.56K | 383 |
| Short-Term Investments | 50.55K | 676.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 15.29K | 7.35K | 0 | 38.98K | 8.07K | 0 | 21.79K | 0 | 0 | 0 |
| Days Sales Outstanding | 8.95 | 1.97 | - | - | - | - | 258.51 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 631.08K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 13.88M | 12.49M | 7.86M | 6.32M | 3.97M | 4.59M | 75.73K | 171.04K | 0 | 46.54K |
| Property, Plant & Equipment | 89.25K | 18.4K | 59.78K | 108.88K | 71.46K | 31.85K | 73.73K | 0 | 0 | 0 |
| Fixed Asset Turnover | 28.78x | 74.08x | - | - | - | 2.35x | 0.42x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 316.09K | 361.25K | 541.88K | 2.55M | 3.55M | 0 | 0 | 0 | 0 | 46.54K |
| Long-Term Investments | 37M | 7.86M | 5.69M | 3.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 313.89K | 4.25M | 1.56M | 158.33K | 348.33K | 4.55M | 2K | 171.04K | 0 | 0 |
| Total Assets | 19.79M | 19.84M | 8.91M | 8.07M | 7.92M | 6.77M | 300.48K | 171.54K | 153.56K | 46.92K |
| Asset Turnover | 0.08x | 0.07x | - | - | - | 0.01x | 0.10x | - | - | - |
| Asset Growth % | 255.36% | 122.71% | 10.38% | 1.96% | 17% | 2151.56% | 75.16% | 11.71% | 227.27% | - |
| Total Current Liabilities | 1.82M | 1.77M | 4.51M | 2.99M | 2.17M | 2.76M | 5.28M | 155.85K | 705.22K | 310.94K |
| Accounts Payable | 1.01M | 888.75K | 1.27M | 1.42M | 99.02K | 134.09K | 1.62M | 450 | 55.22K | 215.94K |
| Days Payables Outstanding | 1.88K | 1.8K | - | - | - | - | 614.7 | - | - | - |
| Short-Term Debt | 100K | 118.88K | 1.19M | 1.01M | 1.89M | 2.42M | 1.88M | 152.64K | 650K | 95K |
| Deferred Revenue (Current) | 2.72M | 599.46K | 0 | 0 | 0 | 0 | 1M | 2.76K | 0 | 0 |
| Other Current Liabilities | 1.23M | 161.05K | 1.28M | 555.95K | 182K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 3.25x | 4.16x | 0.23x | 0.59x | 1.81x | 0.79x | 0.04x | 0.00x | 0.22x | 0.00x |
| Quick Ratio | 3.25x | 4.16x | 0.23x | 0.59x | 1.81x | 0.79x | 0.04x | 0.00x | 0.22x | 0.00x |
| Cash Conversion Cycle | -1.87K | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 317.63K | 528.13K | 768.43K | 1.29M | 1.65M | 164.72K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 150K | 150K | 150K | 150K | 1.65M | 150K | 0 | 0 | 0 |
| Capital Lease Obligations | 18.87K | 0 | 18.88K | 61.18K | 14.72K | 0 | 14.72K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 167.63K | 359.25K | 557.25K | 1.13M | 0 | -1 | 0 | 0 | 0 |
| Total Liabilities | 390.53K | 2.09M | 5.04M | 3.76M | 3.46M | 4.41M | 5.44M | 155.85K | 705.22K | 310.94K |
| Total Debt | 100K | 268.88K | 1.4M | 1.22M | 2.06M | 4.08M | 2.09M | 152.64K | 650K | 95K |
| Net Debt | -5.11M | -5.41M | 866.17K | -244.91K | -1.73M | 1.9M | 1.88M | 152.14K | 496.44K | 94.62K |
| Debt / Equity | 0.01x | 0.02x | 0.36x | 0.28x | 0.46x | 1.74x | - | 9.73x | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | 0.89x | - | 0.04x |
| Net Debt / EBITDA | 0.44x | - | - | - | - | - | - | 0.89x | - | 0.04x |
| Interest Coverage | -20.90x | -18.11x | -26.29x | -196.49x | -171.03x | -70.87x | -60.79x | - | - | - |
| Total Equity | 17.58M | 17.75M | 3.87M | 4.31M | 4.45M | 2.35M | -5.14M | 15.69K | -551.66K | -264.01K |
| Equity Growth % | 653.71% | 359.11% | -10.36% | -3.13% | 89.45% | 145.7% | -32876.84% | 102.84% | -108.95% | - |
| Book Value per Share | 2.91 | 4.19 | 2.01 | 0.17 | 0.31 | 2.30 | -0.25 | 0.00 | -296.11 | -141.71 |
| Total Shareholders' Equity | 17.18M | 17.25M | 3.19M | 4.31M | 4.45M | 2.35M | -5.14M | 15.69K | -551.66K | -264.01K |
| Common Stock | 656 | 575 | 212 | 3.53K | 1.96K | 3.55K | 2.52K | 25K | 1.6K | 3.76K |
| Retained Earnings | -113.87M | -109.95M | -98.23M | -87.36M | -66.09M | -27.55M | -14.1M | -9.31K | -3.33M | -2.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -247.16K | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 401.88K | 506.16K | 682.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent capital dilution risk
As reported in financial statements, Coeptis Therapeutics has seen its total assets fluctuate significantly, reaching $19.8M in 2026Q1, yet this growth is largely decoupled from operational success, as the company continues to accumulate a massive deficit of -$113.9M in retained earnings over the observed period.
The trajectory of the balance sheet suggests a company heavily reliant on external capital injections to offset persistent operational losses. Investors should monitor whether the recent asset expansion reflects genuine value creation or merely the temporary accumulation of cash from dilutive financing activities.
Based on the provided quarterly data, Coeptis Therapeutics' liquidity position remains highly unstable, with the current ratio swinging from a low of 0.23 in 2024Q4 to 3.25 in 2026Q1, indicating that the company's ability to meet short-term obligations is entirely dependent on the timing of capital raises.
The erratic nature of the current ratio highlights a lack of predictable cash flow, which is typical for a pre-commercial biotech firm. The recent improvement in liquidity appears to be a transient result of financing rather than an improvement in the underlying business model's self-sufficiency.
According to the balance sheet data, the company's equity base has been subject to significant volatility, with retained earnings deepening to -$113.9M by 2026Q1, suggesting that shareholder value is being systematically eroded by the ongoing funding requirements of the clinical-stage pipeline.
The persistent negative retained earnings indicate that the company has yet to achieve a profitable operational state. This structure implies that future capital needs will likely be met through further equity issuance, which warrants caution regarding potential dilution for existing shareholders.
As evidenced by the reported figures, the company's asset base is heavily skewed toward intangible assets and goodwill, which peaked at $2.6M in 2023Q4, raising concerns about the potential for future impairment charges if the GEAR platform fails to meet its clinical development milestones.
The reliance on intangible assets suggests that the balance sheet is highly sensitive to the success of the company's intellectual property. If clinical trials do not yield positive results, the carrying value of these assets may be subject to significant write-downs, further weakening the company's financial position.
Quick answers to the most common questions about buying COEP stock.
As of 2025, Coeptis Therapeutics, Inc. (COEP) had total assets of $19.8M including $7.4M in current assets.
Coeptis Therapeutics, Inc. (COEP) carries total debt of $0.3M, offset by $6.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Coeptis Therapeutics, Inc. (COEP) has total shareholders' equity (book value) of $17.2M ($4.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Coeptis Therapeutics, Inc. (COEP) reported a current ratio of 4.16x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.